Cuba's Center for Genetic Engineering and Biotechnology (CIGB) showed new images of the increased immune response with a booster dose of its Covid-19 Abdala (CIGB-66) vaccine.
With the celebration of the Latin American Medicine Day on December 3, Holguín stands as a benchmark for health in eastern Cuba through different centers and services with satisfactory results in improving the quality of life of patients.
In the middle of its high winter tourism season, Cuba offers higher biosafety standards in line with the new post-pandemic normal, and attractive possibilities—other than its culture and nature—such as the availability of health care provided by prestigious professionals.
Cuba is currently working on a specific vaccine to fight the new COVID-19 variant named Omicron, said the President of the Cuban Biotech Conglomerate BioCubaFarma, Eduardo Martinez.
Health workers, students of Medical Sciences and other risk groups, including those from the Tourism sector, the Ministry of the Interior and Transportation in the province of Holguín began to receive single anti-COVID booster doses of Abdala, with the aim of maintaining immunity against the lethal disease.